Oxford Biomedica plc (LSE: OXB)
Health Care · Biotechnology · GB
£5.35
+2.69% today · -19.0% 1Y
Oxford Biomedica plc (LSE: OXB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $834.48M and employs 1,017 people.
Over the last twelve months the share price has lost 19.0%, trading between 4.20 and 9.62.
Tweenvest scores Oxford Biomedica plc across four factors: quality 54/100, value 70/100, growth 100/100. Its strongest factor is growth.
OXB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $834.48M
- Revenue (TTM)
- $232.67M
- P/E
- —
- EPS
- -0.34
- Dividend yield
- —
- Beta (5Y)
- 1.11
- 52-week high
- £9.62
- 52-week low
- £4.20
- Avg volume (3M)
- —
- Shares outstanding
- 121.04M
- Employees
- 1,017
- Next earnings
- —
About Oxford Biomedica plc
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
- ISIN
- GB00BDFBVT43
- Founded
- 1996
- Listed since
- Dec 13, 1996
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PeptiDream Inc.TSE: 4587 | $872.86M | ¥1,075.00 | +2.14% |
| Hangzhou Biotest Biotech Co.,Ltd.SHSE: 688767 | $865.08M | CN¥39.60 | -1.49% |
| Sana Biotechnology, Inc.NasdaqGS: SANA | $835.22M | $2.62 | -6.09% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $834.92M | $4.15 | -1.66% |
| CARsgen Therapeutics Holdings LimitedSEHK: 2171 | $833.26M | HK$11.63 | -6.59% |
| ArriVent BioPharma, Inc.NasdaqGM: AVBP | $824.92M | $16.46 | -1.61% |
| Ardelyx, Inc.NasdaqGM: ARDX | $817.34M | $3.23 | -1.52% |
| Geron CorporationNasdaqGS: GERN | $787.03M | $1.22 | -0.41% |
Figures last refreshed Oct 11, 2026.